Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Cisplatin

Small molecule · Cytotoxic, directed at genomic DNA · developed by Hq Spclt Pharma

Approved FDA, Dec 1978
1 Registered trials

What is Cisplatin?

Cisplatin is a platinum-based small molecule that binds to genomic DNA to form interstrand and intrastrand cross-links, interfering with transcription and DNA replication and triggering cell death.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Targets
genomic DNA
Mechanism
Cytotoxic, directed at genomic DNA
Pathways
DNA cross-linking, transcription inhibition, DNA replication inhibition, apoptosis
Therapy area
Oncology
Developer
Hq Spclt Pharma
In trials of
INO
FDA status
Approved (December 19, 1978), NDA018057 · FDA label
UNII
Q20Q21Q62J

✅ FDA-approved uses

From the indications section of the FDA label (version of Jun 24, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT02501278 Phase 2 Uterine Cervical Neoplasms Withdrawn INO

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Uterine Cervical Neoplasms

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.